Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + TAS-102 second-line maintenance in metastatic colorectal cancer
ChiCTR2500112655Phase 4Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fruquintinib and trifluridine + tipiracil in colorectal cancer (CRC) (2 arms), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Progression-free survival (PFS). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
fruquintinibtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500112655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112655.